Huntington’s disease training courses

Huntington’s disease is rare and complex. We run essential professional development courses for any health social care practitioner working with Huntington’s patients. We’ll help you learn more about Huntington’s, so you can gain a better understanding of the disease and enhance your practice.

Certificated Course for Professionals

Our flagship course for healthcare professionals is a unique opportunity to develop a deeper understanding of Huntington’s, share ideas and discuss the management of complex situations.
You’ll hear from leading consultants from the field of Huntington’s. You’ll learn about topics such as:

  • genetics
  • neuro-psychology
  • psychiatry
  • physiotherapy
  • occupational therapy
  • speech therapy
  • palliative care

Our courses always encourage participants to consider how Huntington’s disease impacts upon individuals and families.

Take a look at our events calendar to see when our next Certificated Course for Professionals is taking place.

Bespoke training

Your local Specialist Huntington’s Disease Adviser can deliver bespoke training online via video chat.

A standard training session covers an overview of Huntington’s disease. The training session lasts for 1 - 1.5 hours and certificates can be provided if needed.

There is a charge of £40 per hour for this session. You are welcome to include as many attendees as you like. 

Your local specialist adviser will be able to discuss your training needs and talk to you about the bespoke training we offer. Get in touch for more information.

Huntington’s Disease Study Group, online training program.

CME4HD - This is a free American online training program in Huntington’s Disease available at

It is a very valuable tool but if undertaken by a professional in the UK this is a non-exclusive list of points to note:

  • CME is the Continuing Medical Education.  As an American course people undertaking the course in the UK are not set up to gain CPD points on completion.
  • All information given on prevalence, laws (i.e. the genetic discrimination act), funding (i.e. for testing and for PIGD), approved medications, capacity assessments and resources etc will be US based and not representative of the situation in the UK.